Table 1

Patient and healthy donor characteristics
Parameter SSc patients (n = 33) Healthy donors (n = 13)
Mean age, years (SD) 55 (13) 43 (7)
Females/males, n (%) 24/9 (73/27) 9/4 (69/31)
Mean anti-AT1R Abs, units (SD) 16 (8) 9 (4)
Mean anti-ETAR Abs, units (SD) 15 (10) 6 (4)
Diffuse cutaneous form, limited cutaneous form, other, n (%) 21 (64), 10 (30), 2 (6) n.a.
Scl 70 positive, n (%), n.d. n (%) 13 (39), 3 (90) n.a.
Anti-centromere positive, n (%), n.d. n (%) 4 (12), 4 (12) n.a.
Duration since Raynaud phenomenon, years (±SD) 10 (11) n.a.
Duration since skin-involvement onset, years (±SD) 9 (7) n.a.
Duration since internal organ onset, years (±SD) 8 (7) n.a.
mRSS median (IQR) 8 (4-18) n.a.
Pulmonary arterial hypertension, n (%)a 14 (42) n.a.
Lung fibrosis, n (%)b 18 (55) n.a.
Mean DLCO% (SD) 50 (20) n.a.
Mean FVC% (SD) 85 (18) n.a.
Animal experiments SSc patients (n = 14) Healthy donors (n = 15)
Mean age, years (SD) 57 (14) 47 (8)
Females/males, n (%) 11/3 (79/21) 12/3 (80/20)
Mean anti-AT1R Abs, units (SD) 18 (10) 6 (4)
Mean anti-ETAR Abs, units (SD) 17 (10) 4 (3)
Diffuse cutaneous form, limited cutaneous form, other, n (%) 10 (71), 3 (21), 0 (0) n.a.
Scl 70 positive, n (%), n.d. n (%) 10 (71), 1 (7) n.a.
Anti-centromere positive, n (%), n.d. n (%) 2 (14), 3 (21) n.a.
Duration since Raynaud phenomenon, years (±SD) 11 (8) n.a.
Duration since skin-involvement onset, years (±SD) 10 (7) n.a.
Duration since internal-organ onset, years (±SD) 10 (9) n.a.
mRSS median (IQR) 8.5 (5.3-11) n.a.
Pulmonary arterial hypertension, n (%)a 8 (57) n.a.
Lung fibrosis, n (%)b 8 (57) n.a.
Mean DLCO% (SD) 42 (18) n.a.
Mean FVC% (SD) 77 (19) n.a.

n.d., not defined; n.a., not applicable.

aBy >35 mm Hg sPAP in echocardiography and/or 25 mm Hg mPAP in right-heart catheterization.

bBy HR-CT or x-ray.

Kill et al.

Kill et al. Arthritis Research & Therapy 2014 16:R29   doi:10.1186/ar4457

Open Data